ECSP22037602A - Antagonistas heterocíclicos de nmda - Google Patents
Antagonistas heterocíclicos de nmdaInfo
- Publication number
- ECSP22037602A ECSP22037602A ECSENADI202237602A ECDI202237602A ECSP22037602A EC SP22037602 A ECSP22037602 A EC SP22037602A EC SENADI202237602 A ECSENADI202237602 A EC SENADI202237602A EC DI202237602 A ECDI202237602 A EC DI202237602A EC SP22037602 A ECSP22037602 A EC SP22037602A
- Authority
- EC
- Ecuador
- Prior art keywords
- nmda antagonists
- heterocyclic
- heterocyclic nmda
- migraine
- dementia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206311A JP2021080177A (ja) | 2019-11-14 | 2019-11-14 | 複素環化合物及びその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22037602A true ECSP22037602A (es) | 2022-06-30 |
Family
ID=74141594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202237602A ECSP22037602A (es) | 2019-11-14 | 2022-05-12 | Antagonistas heterocíclicos de nmda |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20230002318A1 (https=) |
| EP (1) | EP4058430A1 (https=) |
| JP (3) | JP2021080177A (https=) |
| KR (1) | KR20220102629A (https=) |
| CN (1) | CN114728900A (https=) |
| AR (1) | AR120452A1 (https=) |
| AU (1) | AU2020385250A1 (https=) |
| BR (1) | BR112022008367A2 (https=) |
| CA (1) | CA3158352A1 (https=) |
| CL (1) | CL2022001241A1 (https=) |
| CO (1) | CO2022008012A2 (https=) |
| CR (1) | CR20220275A (https=) |
| DO (1) | DOP2022000099A (https=) |
| EC (1) | ECSP22037602A (https=) |
| IL (1) | IL292639A (https=) |
| JO (1) | JOP20220108A1 (https=) |
| MX (1) | MX2022005778A (https=) |
| PE (1) | PE20221767A1 (https=) |
| PH (1) | PH12022551173A1 (https=) |
| TW (1) | TWI908745B (https=) |
| WO (1) | WO2021094832A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220160A (es) | 2019-09-16 | 2022-06-16 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2026060343A1 (en) | 2024-09-16 | 2026-03-19 | Neurocrine Biosciences, Inc. | Solid forms comprising a nr2b nam antagonist |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| WO2000017162A1 (en) * | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Novel thiol derivatives, process for producing the same and utilization thereof |
| JP2000159747A (ja) * | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| AU1153601A (en) * | 1999-10-29 | 2001-05-08 | Merck Sharp & Dohme Limited | Method to treat pain utilizing benzimidazole NMDA NR2B antagonists |
| JPWO2003035641A1 (ja) * | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| JP2004002405A (ja) * | 2002-04-26 | 2004-01-08 | Takeda Chem Ind Ltd | 新規チオール誘導体、その製造法および用途 |
| AU2003235121A1 (en) | 2002-04-26 | 2003-11-10 | Takeda Pharmaceutical Company Limited | Novel thiol derivative, process for producing the same and use thereof |
| TW200732313A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
| TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| PL3110434T3 (pl) | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| CN107074788B (zh) * | 2014-10-31 | 2019-09-20 | 厦门大学 | 取代杂环衍生物、其制备方法和用途 |
| WO2018205935A1 (zh) | 2017-05-09 | 2018-11-15 | 浙江大学 | 治疗抑郁症的方法和药物组合物 |
| JP6806735B2 (ja) | 2018-05-30 | 2021-01-06 | 矢崎総業株式会社 | 車両用回路体および車両用回路体の製造方法 |
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| CA3134545A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
-
2019
- 2019-11-14 JP JP2019206311A patent/JP2021080177A/ja active Pending
-
2020
- 2020-11-12 EP EP20838595.5A patent/EP4058430A1/en active Pending
- 2020-11-12 CN CN202080079710.1A patent/CN114728900A/zh active Pending
- 2020-11-12 TW TW109139608A patent/TWI908745B/zh active
- 2020-11-12 MX MX2022005778A patent/MX2022005778A/es unknown
- 2020-11-12 BR BR112022008367A patent/BR112022008367A2/pt unknown
- 2020-11-12 JP JP2022527713A patent/JP7726879B2/ja active Active
- 2020-11-12 US US17/755,907 patent/US20230002318A1/en active Pending
- 2020-11-12 PE PE2022000751A patent/PE20221767A1/es unknown
- 2020-11-12 AR ARP200103139A patent/AR120452A1/es unknown
- 2020-11-12 AU AU2020385250A patent/AU2020385250A1/en active Pending
- 2020-11-12 WO PCT/IB2020/000962 patent/WO2021094832A1/en not_active Ceased
- 2020-11-12 CR CR20220275A patent/CR20220275A/es unknown
- 2020-11-12 PH PH1/2022/551173A patent/PH12022551173A1/en unknown
- 2020-11-12 CA CA3158352A patent/CA3158352A1/en active Pending
- 2020-11-12 KR KR1020227019888A patent/KR20220102629A/ko active Pending
-
2022
- 2022-05-01 IL IL292639A patent/IL292639A/en unknown
- 2022-05-10 JO JOP/2022/0108A patent/JOP20220108A1/ar unknown
- 2022-05-12 EC ECSENADI202237602A patent/ECSP22037602A/es unknown
- 2022-05-12 CL CL2022001241A patent/CL2022001241A1/es unknown
- 2022-05-13 DO DO2022000099A patent/DOP2022000099A/es unknown
- 2022-06-06 CO CONC2022/0008012A patent/CO2022008012A2/es unknown
- 2022-12-22 US US18/087,233 patent/US11834409B2/en active Active
- 2022-12-22 US US18/087,302 patent/US11827601B2/en active Active
-
2025
- 2025-08-07 JP JP2025132388A patent/JP2025159062A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728900A (zh) | 2022-07-08 |
| US11827601B2 (en) | 2023-11-28 |
| AR120452A1 (es) | 2022-02-16 |
| DOP2022000099A (es) | 2022-08-31 |
| WO2021094832A1 (en) | 2021-05-20 |
| EP4058430A1 (en) | 2022-09-21 |
| CR20220275A (es) | 2023-02-17 |
| PH12022551173A1 (en) | 2024-02-19 |
| WO2021094832A8 (en) | 2022-06-02 |
| JOP20220108A1 (ar) | 2023-01-30 |
| JP7726879B2 (ja) | 2025-08-20 |
| CO2022008012A2 (es) | 2022-06-10 |
| JP2021080177A (ja) | 2021-05-27 |
| TWI908745B (zh) | 2025-12-21 |
| BR112022008367A2 (pt) | 2022-10-18 |
| US20230134307A1 (en) | 2023-05-04 |
| AU2020385250A1 (en) | 2022-06-30 |
| TW202132268A (zh) | 2021-09-01 |
| JP2025159062A (ja) | 2025-10-17 |
| JP2023502030A (ja) | 2023-01-20 |
| CA3158352A1 (en) | 2021-05-20 |
| PE20221767A1 (es) | 2022-11-11 |
| US20230150934A1 (en) | 2023-05-18 |
| US11834409B2 (en) | 2023-12-05 |
| CL2022001241A1 (es) | 2023-02-03 |
| IL292639A (en) | 2022-07-01 |
| KR20220102629A (ko) | 2022-07-20 |
| US20230002318A1 (en) | 2023-01-05 |
| MX2022005778A (es) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022008012A2 (es) | Antagonistas heterocíclicos de nmda | |
| GEAP202215540A (en) | Pcsk9 antagonist compounds | |
| MX2023009527A (es) | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. | |
| EA202091506A1 (ru) | Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa | |
| MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2019014445A (es) | Preparacion hidratante topica. | |
| MX378566B (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| BR112018011154A2 (pt) | dispersões sólidas compreendendo um estimulador de sgc | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| ZA202305624B (en) | Amorphous form of a complement component c5a receptor | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| JOP20220160A1 (ar) | مركبات فعّالة نحو مستقبلات نووية | |
| MX2021001209A (es) | Composiciones oleaginosas topicas. | |
| MX384468B (es) | Composiciones que comprenden bacillus coagulans sbc37-01, mtcc 5856 para el tratamiento del síndrome de intestino irritable con diarrea predominante. | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| GEAP201814255A (en) | P-substituted asymmetric ureas and medical uses thereof | |
| AU2019241765A8 (en) | Heterocyclic compound and use thereof | |
| PH12022551578A1 (en) | Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| UA122811C2 (uk) | Фармацевтична композиція | |
| MX2021014705A (es) | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. | |
| PL426157A1 (pl) | Zastosowanie medyczne 4-(2-fluorofenylo)-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu |